China NMPA Drug Inspection - Chifeng Weikang Biochemical Pharmaceutical Co., Ltd. - Enalapril hydrochlorothiazide dispersible tablets
China NMPA drug inspection for Chifeng Weikang Biochemical Pharmaceutical Co., Ltd. published May 11, 2017. Drug: Enalapril hydrochlorothiazide dispersible tablets. The State Food and Drug Administration (SFDA) announced on May 11, 2017, findings from drug testing that identified 11 b
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Chifeng Weikang Biochemical Pharmaceutical Co., Ltd. published May 11, 2017. Drug: Enalapril hydrochlorothiazide dispersible tablets. The State Food and Drug Administration (SFDA) announced on May 11, 2017, findings from drug testing that identified 11 b
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox